先声药业集团有限公司（02096）于2026年3月26日公告，披露该公司在香港联交所场内回购股份。根据公告，公司本次回购股份数量为1,974,000股，占已发行股本约0.076%。每股回购价介乎港币10.9444元至11.3272元，合计耗资约22,032,406港元（约2,203.24万港元）。
本次回购完成后，公司已发行股本维持在2,595,697,618股，库藏股数为0股。公司此前于2025年6月13日获得购回授权，授权可购回的总数为247,469,761股；截至目前，已根据购回授权回购12,825,000股，占授权决议通过当日公司已发行股本约0.5182%。
公告同时指出，公司确认已遵守香港联交所证券上市规则及其他相关法律规定。本公告由执行董事及联席公司秘书万玉山签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.